Incorporated in 1994, Tasly Holding Group has since developed into an international and high-tech cooperation, engaging in the pan-health industry with the biological medicine industry as the core business, while the healthcare industry and medical services serve as the two supporting businesses.
Tasly aims to become No. 1 in modern biological pharmaceuticals and a leader of the integrated healthcare industry in China. Its six core industries include biopharma, health products, herbal medicine industry, medical devices, health management, and child education.
As the core enterprise of the Holding Group, Tasly Pharmaceutical Group (SHA: 600535) is one of the largest pharmaceutical companies in China with more than 20 years of operational history. Its business focuses on R&D, manufacturing and commercialization of innovative modern traditional Chinese medicine, biologics and chemical drugs in the therapeutic areas of cardiology, metabolism and oncology.
In 2006, Tasly founded its overseas headquarters, Tasly Pharmaceuticals, Inc. (TaslyUS), in Rockville, Maryland. It has become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals. Their T89 (Dantonic) is the first herbal medicine-derived compound to complete an FDA Phase III global clinical trial with promising data.
In 2018, the company invested in three overseas original drug projects. In June, Tokyo-based company EA Pharma signed a license agreement to grant Tasly the exclusive rights to develop and market a secondary hyperparathyroidism treatment agent (Code: AJT240) in China. The same year in October, Tasly established a strategic partnership with Mesoblast Limited (Nasdaq: MESO; ASX: MSB) for its allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for heart failure and MPC-25-IC for heart attacks. Mesoblast has received US$40 million in support from Tasly, comprising an upfront technology access fee of US$20 million.It has also received an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly.
In 1997, the company’s technical center, Tasly Medical R&D Center, was founded. It is responsible for scientific research, technical research, and product development. Through years of development, it has become a modern technical center with advanced equipment, a rational structure, and a functional system. In recent years, Tasly has invested more funds in scientific R&D. Investment in scientific R&D has taken up over 10% of its sales revenue for four consecutive years.
Tasly also agreed to extensive collaborations with many overseas scientific research institutes and universities such as Harvard University, Aston University in England, Baker Medical Research Institute in Australia, and others. Thus, it has accomplished a powerful scientific researching system with Tasly’s characteristics.
Products & Market
Tasly has been seeking to develop within the international market since its foundation. By now, more than 30 types of preparation products in 8 medical categories are available on the global market. Their export teams cover 23 countries in America, Europe, Africa, and Asia. With the distribution network spreading to more than 40 countries, Tasly’s distributor members have almost reached a million globally.
Tasly has set up two organizing systems of international trade and international direct sales, and a global marketing mode of expanding from developing countries to developed countries. The include Asian area centered in Malaysia and Korea, a European Area centered in Holland and France, a North American Area centered in the United States, and an African Area centered in South Africa and Nigeria.